Downstream Processing

Best before... Image: StanleyD

Cell Therapy Manufacturing & Gene Therapy Congress - Brussels, Belgium

Short shelf-life poses problems for cell therapy makers, Chiesi

By Dan Stanton

The shelf life of a cell therapy product is crucial in determining a firm’s manufacturing strategy according to the makers of the first approved stem-cell based drug.

Rendering of new 300,000 square foot facility (PRNewsFoto/N.Y. State Executive Chamber)

Athenex to invest $1.62bn in biotech facilities

By Melissa Fassbender

Athenex will invest a minimum of $1.62 bn over the next ten years in labor, materials, and supplies, to create a new manufacturing facility and to expand its North American headquarters.

The mAbs has been approved to begin clinical trials

CNS drugmaker teams with CDMO on ALS mAb candidate

By Fiona BARRY

CDMO (contract development and manufacturing organisation) Goodwin Biotechnology is working with CNS biotech Q Therapeutics to produce mAbs for a clinical trial to treat motor neuron disease.

apceth expands gene, cell therapy manufacturing business

apceth expands gene, cell therapy manufacturing business

By Zachary Brennan

German-based contract manufacturer apceth has received regulatory approval to use two new GMP cleanrooms for aseptic processing, which will be used for the handling and genetic manipulation of various types of cell and gene therapies.